CClinicalTrials.gg
Status unknownNCT03263299Updated Aug 28, 2017

Value of Cabergoline and Low Dose Aspirin in Poor Responders Undergoing ICSI-ET With GnRH Agonist Flare-Up-Protocol

A Phase 4 interventional study of cabergoline and Aspirin in Invitro Fertilization, sponsored by Cairo University. Status unknown at 1 site in Egypt. Open to female participants aged 20 Years to 39 Years. Per ClinicalTrials.gov, last updated 2017-08-28.

Sponsored by Cairo University · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2017), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
20 Years to 39 Years
Sex
Female
01

Study summary

Ovarian stimulation will be done using the Microdose flare-up regimen. The patient will receive diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation will be initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day.

Follicular monitoring began from the ninth day of the cycle by serial vaginal ultrasonography and measurement of serum E2 levels. IM injections of 10000 IU HCG (Choriomon; IBSA, Germany) will be injected when at least 2 follicles 18 mm were observed on ultrasonography.

Oocytes willbe retrieved 36 hours after hCG injection using a 17-gauge aspiration needle under transvaginal ultrasound guidance. The pelvis is evaluated with ultrasound to ensure that there is no internal bleeding.

After fertilization was confirmed when two polar bodies and two pronuclear were observed 18-20 hours after insemination, one to three grade A embryos were transferred at day 3 fertilization.

The luteal phase support will be initiated from the day of oocyte retrieval for all patients with (Cyclogest 400 mg, Actavis pharmaceutical, UK) vaginal suppositories per day till the day of serum pregnancy test was done.

Read the detailed description

Ovarian stimulation was done using the Microdose flare-up regimen. The patient received diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation is initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day.

Follicular monitoring began from the ninth day of the cycle by serial vaginal ultrasonography and measurement of serum E2 levels. IM injections of 10000 IU HCG (Choriomon; IBSA, Germany) were injected when at least 2 follicles 18 mm were observed on ultrasonography.

Oocytes were retrieved 36 hours after hCG injection using a 17-gauge aspiration needle under transvaginal ultrasound guidance. The pelvis is evaluated with ultrasound to ensure that there is no internal bleeding.

After fertilization was confirmed when two polar bodies and two pronuclear were observed 18-20 hours after insemination, one to three grade A embryos were transferred at day 3 fertilization.

The luteal phase support was initiated from the day of oocyte retrieval for all patients with (Cyclogest 400 mg, Actavis pharmaceutical, UK) vaginal suppositories per day till the day of serum pregnancy test was done.

Serum β-hCG was performed 14 days after the embryo transfer to confirm chemical pregnancy. Clinical pregnancy was confirmed when there was an evidence of gestational sac, embryo and fetal heart activity at time of transvaginal ultrasound evaluation by the 6th week.

02

Conditions studied

  • Invitro Fertilization
03

Who can participate

Ages eligible
20 Years to 39 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  1. Patients with a history of one or more failed IVF cycles with three or less retrieved oocytes
  2. No age limitation
  3. Patients with an inadequate ovarian response in previous cycle
  4. Low estradiol (E2) levels in response to ovarian stimulation in previous cycle
  5. Lower number of retrieved oocytes in previous trials.

Exclusion criteria

Exclusion Criteria:

  1. Severe male factor (azospermia)
  2. Hydrosalpinx
  3. History of endometriosis
  4. Endocrine or metabolic disorders
  5. Follicle stimulating hormone (FSH) level > 15 mIU.
  6. Antimullerian hormone (AMH)\< 0.5 ng/ml
  7. Any uterine causes of infertility e.g. septate uterus
04

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    cabergoline group

    received cabergoline in addition to aspirin. Cabergoline was administered in a dose of 1 mg/week in two divided doses which was terminated after embryo transfer. Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide

    Drug: cabergoline · Drug: Aspirin · Drug: GnRH agonist

  • Active comparator
    Aspirin group

    Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide

    Drug: Aspirin · Drug: GnRH agonist

  • Active comparator
    GnRH Group

    Microdose flare-up regimen. The patient received diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation is initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day.

    Drug: GnRH agonist

Interventions

  • Drugcabergoline

    Cabergoline was administered in a dose of 1 mg/week in two divided doses which was terminated after embryo transfer

  • DrugAspirin

    Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide

  • DrugGnRH agonist

    Microdose flare-up regimen. The patient received diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation is initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day.

05

What researchers measure

Primary outcomes

  1. clinical pregnancy

    Intrauterine gestational sac detection by transvaginal ultrasound

    Time frame: 4 weeks after embryo transfer

06

Study locations

1 site
  • Kasr Alainy medical school
    Cairo, 12151, Egypt
07

Registry details

Key details

Study ID
NCT03263299
Lead sponsor
Cairo University
Responsible party
Ahmed Maged (Professor, Cairo University) — Principal investigator
First posted
Aug 28, 2017
Start date
Aug 2017 (estimated)
Primary completion
Aug 2018 (estimated)
Completion
Sep 2018 (estimated)
Last update
Aug 28, 2017

Study contacts

Ahmed Maged, MD
Contact
prof.ahmedmaged@gmail.com
01005227404
Ayman Hany, MD
Contact
aymanobgyn@gmail.com
Ahmed Maged, MD
principal investigator · kasr Alainy medical school

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion